VIVO - Meridian acquires EUPROTEIN to expand recombinant protein capabilities

Meridian Bioscience (NASDAQ:VIVO) has acquired, through its subsidiary Meridian Life Science substantially all of the assets of EUPROTEIN. The transaction closed on April 30, 2022. EUPROTEIN offers custom development and production of high-quality bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies. The acquisition will help Meridian accelerate its pipeline of new immunological reagents while expanding recombinant capabilities.

For further details see:

Meridian acquires EUPROTEIN to expand recombinant protein capabilities